Atara Biotherapeutics Inc
0HIY.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$85.42M
Close$
Share Statistics
| Market cap | $85.42 Million |
|---|---|
| Enterprise Value | $92.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.61 |
| Beta | 0.1 |
| Outstanding Shares | 15,033,000 |
Return
| Return on Equity | 45.11% |
|---|---|
| Return on Assets | -79.38% |
| Return on Invested Capital | -107.89% |
Valuation & Multiples
| P/E Ratio | -8.03 |
|---|---|
| PEG | 2.66 |
| Price to Sales | - |
| Price to Book Ratio | -3.01 |
| Enterprise Value to Revenue | 33.87 |
| Enterprise Value to EBIT | -6.07 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | -0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$550,000
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$800,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Atara Biotherapeutics Inc
14 employees
CEO: Pascal Touchon Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseas...